· EBITDA at £6.7m (2019 restated : £1.7m) · Profit before taxation of £4.5m (2019 restated profit : £1.1m) · Profit after taxation of £3.9m (2019 restated profit : £1.3m) · Earnings per share of 3.13p (2019: restated Earnings per share : 1.68p) · Cash generated by operations of £3.5m (2019 restated : £1.3m) · Net cash at 30th September 2020 of £12.9m (2019: £13.4m) Prior period figures have been restated to reflect adjustments arising from the March 2020 audit. Operations · USA recovery following the easing in geopolitical trade tensions between China and the USA · Latin America performing strongly, led by Brazil · New marketing authorisation from the European Medicines Agency for the use of Aivlosin® 625 mg/g Water Soluble Granules in pigs for the treatment of Mycoplasma hyopneumoniae